All Stories

  1. A 14-Year Longitudinal Analysis of Healthcare Expenditure on Dementia and Related Factors (DEMENCOST Study)

    Article • Journal of Alzheimer’s Disease, July 2023, IOS Press

    Dr Jose M. Inoriza

  2. Morbilidad y estado de salud autopercibido, dos aproximaciones diferentes al estado de salud

    Article • Gaceta Sanitaria, November 2020, Elsevier

    Dr Jose M. Inoriza

  3. Survival, effect measures, and impact numbers after dementia diagnosis: a matched cohort study

    Article • Clinical Epidemiology, July 2019, Dove Medical Press

    Dr Josep Garre-Olmo, Anna Ponjoan, Dr Jose M. Inoriza

  4. Ageing and healthcare expenditures: Exploring the role of individual health status

    Article • Health Economics, February 2018, Wiley

    Dr Jose M. Inoriza

  5. Evaluación de la efectividad de un programa de atención integrada y proactiva a pacientes crónicos complejos

    Article • Gaceta Sanitaria, January 2018, Elsevier

    Dr Jose M. Inoriza

  6. Los grupos de morbilidad ajustados: un debate pendiente

    Article • Atención Primaria, August 2017, Elsevier

    Dr Jose M. Inoriza

  7. ¿Son los grupos de morbilidad ajustados concordantes con el criterio clínico de intervención en una estrategia de crónicos?

    Article • Atención Primaria, May 2017, Elsevier

    Dr Jose M. Inoriza

  8. Efectividad e impacto económico de un programa de atención integrada con soporte de telemedicina a pacientes diabéticos tipo 2 tratados con insulina (estudio GITDIABE)

    Article • Atención Primaria, March 2017, Elsevier

    Dr Jose M. Inoriza

  9. Analysing the Costs of Integrated Care: A Case on Model Selection for Chronic Care Purposes

    Article • International Journal of Integrated Care, August 2016, Ubiquity Press, Ltd.

    Dr Jose M. Inoriza

  10. Predicción del riesgo individual de alto coste sanitario para la identificación de pacientes crónicos complejos

    Article • Gaceta Sanitaria, July 2014, Elsevier

    Dr Jose M. Inoriza

  11. Análisis de la población diabética de una comarca: perfil de morbilidad, utilización de recursos, complicaciones y control metabólico

    Article • Atención Primaria, November 2013, Elsevier

    Dr Jose M. Inoriza

  12. Estimating lifetime healthcare costs with morbidity data

    Article • BMC Health Services Research, October 2013, Springer Science + Business Media

    Dr Jose M. Inoriza

  13. Late rectal and bladder toxicity following radiation therapy for prostate cancer: Predictive factors and treatment results

    Article • Reports of Practical Oncology & Radiotherapy, September 2013, VM Media SP. zo.o VM Group SK

    Dr Jose M. Inoriza

  14. Hyperbaric Oxygen Therapy for Late Rectal and Bladder Toxicity after Radiation in Prostate Cancer Patients. A Symptom Control and Quality-of-life Study

    Article • Clinical Oncology, October 2012, Elsevier

    Dr Jose M. Inoriza

  15. Hyperbaric oxygen therapy for carbon monoxide poisoning

    Article • Intensive Care Medicine, June 2011, Springer Science + Business Media

    Dr Jose M. Inoriza

  16. EFFICACY OF HYPERBARIC OXYGEN THERAPY (HBO) FOR LATE PELVIC RADIATION TOXICITY. RESULTS OF A PROSPECTIVE STUDY

    Article • Radiotherapy and Oncology, March 2011, Elsevier

    Dr Jose M. Inoriza

  17. Mitochondrial Injury in Human Acute Carbon Monoxide Poisoning: The Effect of Oxygen Treatment

    Article • Journal of Environmental Science and Health Part C, February 2011, Taylor & Francis

    Dr Jose M. Inoriza

  18. Estimates of patient costs related with population morbidity: can indirect costs affect the results?

    Article • The European Journal of Health Economics, March 2010, Springer Science + Business Media

    Dr Jose M. Inoriza

  19. 16 Mitochondrial damage in acute carbon monoxide poisoning: The effect of oxygen treatment

    Article • Mitochondrion, March 2010, Elsevier

    Dr Jose M. Inoriza

  20. La medida de la morbilidad atendida en una organización sanitaria integrada

    Article • Gaceta Sanitaria, January 2009, Elsevier

    Dr Jose M. Inoriza

  21. Hybrid Risk Adjustment for Pharmaceutical Benefits

    Article • SSRN Electronic Journal, January 2009, Elsevier

    Dr Jose M. Inoriza

  22. Hybrid risk adjustment for pharmaceutical benefits

    Article • The European Journal of Health Economics, November 2008, Springer Science + Business Media

    Dr Jose M. Inoriza

  23. Interval from diagnosis to treatment onset for six major cancers in Catalonia, Spain

    Article • Cancer Detection and Prevention, January 2008, Elsevier

    Dr Jose M. Inoriza

  24. Population Based Resource Allocation: The Use of Hybrid Risk Adjustment

    Article • SSRN Electronic Journal, January 2008, Elsevier

    Dr Jose M. Inoriza

  25. Hybrid Risk Adjustment for Total Health Expenditures

    Article • SSRN Electronic Journal, January 2007, Elsevier

    Dr Jose M. Inoriza